TARGETING THE AP-1 TRANSCRIPTION FACTOR TO PREVENT METASTASIS FROM BREAST CANCER

靶向 AP-1 转录因子预防乳腺癌转移

基本信息

  • 批准号:
    8117278
  • 负责人:
  • 金额:
    $ 13.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-18 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The candidate of this application is a physician scientist who obtained medical and basic biomedical research education, and completed postdoctoral research training in cancer biology. In the past ten years, the candidate has been extensively trained in cellular, molecular, and cancer biology. Immediate career goal of the candidate is to establish an independent research program to study cancer metastasis. Long-term goal is to lead independent research programs to identify targets and develop effective strategies for the prevention and treatment of cancer, and cancer metastasis. The candidate chooses to study metastasis because it counts for 90% of cancer death, while the molecular mechanisms for metastasis development are largely unknown. The elucidation of these processes may lead to the discovery of targets for effective intervention and will benefit cancer patients. The candidate is committed to a research career in cancer biology. The candidate's training and expertise in basic and clinical sciences well fit in his commitment to find a cure for cancer. The key elements of the research career plan includes a solid postdoctoral research training, a productive publication record, an important research field in cancer biology, and Baylor College of Medicine as the supporting environment that will foster candidate's career development. Breast cancer is the 2nd most common cancer in Western women, and metastasis to other organs is the major cause of death from this disease. The 5-year survival rate is approximately 98% for localized cancer, but approximately 26% for patients with distant metastasis. To date, there are no effective therapies for the prevention and treatment of metastasis from breast cancer. It is therefore an absolute clinical necessity to identify new strategies to treat established metastasis and to block the development of new metastasis. Many genes or set of genes regulate cancer metastasis. Transcription factors control the expression of these genes critical for metastasis, and thus are potential targets for intervention. The AP-1 transcription factor has been shown to regulate metastasis-related genes in breast cancer, and overexpression of a major component of AP- 1, cJun, produces a highly invasive phenotype. The candidate will test the hypothesis that the AP-1 factor is required for developing metastasis by mediating metastatic cell invasion, promoting transendothelial migration, stimulating new blood vessel formation, and regulating critical genes involved in metastasis; and blockade of AP-1 will inhibit invasion and migration of metastatic cells, prevent development of new metastasis, and suppress the growth of existing metastasis. Our objective is to define the role of AP-1 in cancer metastasis and blockade of AP-1 is an effective strategy to prevent and treat metastasis. Specifically, the candidate will (1) determine whether AP-1 is required for invasion and metastasis using xenograft and transgenic mouse models; (2) investigate whether AP-1 promotes transendothelial migration, new blood vessel formation; and (3) define the molecular mechanisms how AP-1 regulates migration and invasion by mediating E-cadherin, a major AP-1-regulated gene involved in metastasis. The proposed studies will determine whether the AP-1 factor is a major regulator of metastasis and provide the foundation and rationale to develop agents capable of disrupting the metastatic process. PUBLIC HEALTH RELEVANCE: We hypothesized that the AP-1 factor is required for developing metastasis by mediating metastatic cell invasion, promoting transendothelial migration, stimulating new blood vessel formation, and regulating critical gene expression involved in metastasis. The proposed studies will determine whether the AP-1 factor is a major regulator of metastasis. Results from this project will provide the foundation and rationale to develop agents capable of disrupting the metastatic process.
描述(由申请人提供):本申请的候选人是医生科学家,他们获得了医学和基础生物医学研究教育,并完成了癌症生物学的博士后研究培训。在过去的十年中,候选人在细胞,分子和癌症生物学方面进行了广泛的培训。候选人的直接职业目标是建立一个独立的研究计划来研究癌症转移。长期目标是领导独立的研究计划,以识别目标并制定有效的预防癌症和癌症转移的策略。候选人选择研究转移,因为它计算出90%的癌症死亡,而转移发展的分子机制在很大程度上尚不清楚。阐明这些过程可能会导致发现有效干预的靶标,并将使癌症患者受益。候选人致力于癌症生物学研究生涯。候选人在基础和临床科学方面的培训和专业知识非常适合他寻找治疗癌症的承诺。研究职业计划的关键要素包括一项可靠的博士后研究培训,生产性出版物记录,癌症生物学的重要研究领域以及贝勒医学院作为支持环境,将促进候选人的职业发展。 乳腺癌是西方女性的第二个最常见的癌症,对其他器官的转移是该疾病的主要死亡原因。局部癌症的5年生存率约为98%,远处转移患者约为26%。迄今为止,尚无有效的预防和治疗转移乳腺癌的疗法。因此,确定治疗已建立转移并阻止新转移的新策略的绝对临床必要性。许多基因或一组基因调节癌症转移。转录因子控制这些基因对转移至关重要的表达,因此是干预的潜在靶标。已显示AP-1转录因子在乳腺癌中调节与转移相关的基因,并且AP-1的主要成分CJUN的过表达产生高度侵入性的表型。候选人将通过介导转移性细胞侵袭,促进跨内皮迁移,刺激新的血管形成并调节涉及转移的关键基因来检验AP-1因子来发展转移所必需的AP-1因子。 AP-1的封锁将抑制转移细胞的侵袭和迁移,防止新转移的发展并抑制现有转移的生长。我们的目标是确定AP-1在癌症转移中的作用,而AP-1的阻断是预防和治疗转移的有效策略。具体而言,候选人(1)使用异种移植和转基因小鼠模型确定是否需要AP-1进行侵袭和转移; (2)研究AP-1是否促进了跨内皮迁移,新的血管形成; (3)定义分子机制通过介导e-钙粘着蛋白(一种参与转移的主要AP-1调节基因)来调节迁移和侵袭。拟议的研究将确定AP-1因子是否是转移的主要调节剂,并为开发能够破坏转移过程的试剂提供基础和理由。 公共卫生相关性:我们假设通过介导转移性细胞侵袭,促进跨内皮迁移,刺激新血管形成以及调节涉及转移中涉及的关键基因表达来发展转移所必需的AP-1因子。拟议的研究将确定AP-1因子是否是转移的主要调节剂。该项目的结果将为开发能够破坏转移过程的代理提供基础和理由。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Qiang Shen其他文献

Qiang Shen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Qiang Shen', 18)}}的其他基金

Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer
HJC0152 靶向葡萄糖代谢治疗转移性乳腺癌
  • 批准号:
    10239029
  • 财政年份:
    2018
  • 资助金额:
    $ 13.74万
  • 项目类别:
Chemoprevention of Breast Cancer by Targeting Glucose Metabolism with HJC0152
HJC0152 通过靶向葡萄糖代谢来化学预防乳腺癌
  • 批准号:
    10599984
  • 财政年份:
    2018
  • 资助金额:
    $ 13.74万
  • 项目类别:
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer
HJC0152 靶向葡萄糖代谢治疗转移性乳腺癌
  • 批准号:
    10703216
  • 财政年份:
    2018
  • 资助金额:
    $ 13.74万
  • 项目类别:
Chemoprevention of Breast Cancer by Targeting Glucose Metabolism with HJC0152
HJC0152 通过靶向葡萄糖代谢来化学预防乳腺癌
  • 批准号:
    10402887
  • 财政年份:
    2018
  • 资助金额:
    $ 13.74万
  • 项目类别:
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer
HJC0152 靶向葡萄糖代谢治疗转移性乳腺癌
  • 批准号:
    10439804
  • 财政年份:
    2018
  • 资助金额:
    $ 13.74万
  • 项目类别:
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer
HJC0152 靶向葡萄糖代谢治疗转移性乳腺癌
  • 批准号:
    10017168
  • 财政年份:
    2018
  • 资助金额:
    $ 13.74万
  • 项目类别:
Chemoprevention of Breast Cancer by Targeting Glucose Metabolism with HJC0152
HJC0152 通过靶向葡萄糖代谢来化学预防乳腺癌
  • 批准号:
    10239256
  • 财政年份:
    2018
  • 资助金额:
    $ 13.74万
  • 项目类别:
TARGETING THE AP-1 TRANSCRIPTION FACTOR TO PREVENT METASTASIS FROM BREAST CANCER
靶向 AP-1 转录因子预防乳腺癌转移
  • 批准号:
    7934501
  • 财政年份:
    2009
  • 资助金额:
    $ 13.74万
  • 项目类别:
TARGETING THE AP-1 TRANSCRIPTION FACTOR TO PREVENT METASTASIS FROM BREAST CANCER
靶向 AP-1 转录因子预防乳腺癌转移
  • 批准号:
    8011392
  • 财政年份:
    2009
  • 资助金额:
    $ 13.74万
  • 项目类别:
TARGETING THE AP-1 TRANSCRIPTION FACTOR TO PREVENT METASTASIS FROM BREAST CANCER
靶向 AP-1 转录因子预防乳腺癌转移
  • 批准号:
    7788055
  • 财政年份:
    2009
  • 资助金额:
    $ 13.74万
  • 项目类别:

相似国自然基金

磁性功能微球在核酸快速提取及检测中的基础科学问题探究
  • 批准号:
    52373131
  • 批准年份:
    2023
  • 资助金额:
    50.00 万元
  • 项目类别:
    面上项目
极端高温环境流动沸腾技术的基础科学问题及关键材料研究
  • 批准号:
    52333015
  • 批准年份:
    2023
  • 资助金额:
    230 万元
  • 项目类别:
    重点项目
先进航空发动机中超临界态煤油燃烧过程中的基础科学问题研究
  • 批准号:
    52336006
  • 批准年份:
    2023
  • 资助金额:
    230 万元
  • 项目类别:
    重点项目
企业基础科学研究的动因、机制与经济效果研究
  • 批准号:
    72302229
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
耐高温高电压SiC功率器件灌封材料的多性能协同中的基础科学问题研究
  • 批准号:
    52272001
  • 批准年份:
    2022
  • 资助金额:
    54 万元
  • 项目类别:
    面上项目

相似海外基金

A New Paradigm to Treat Bleeding by Augmenting Hemostasis via Microscale Electrical Fields
通过微尺度电场增强止血来治疗出血的新范例
  • 批准号:
    10612469
  • 财政年份:
    2021
  • 资助金额:
    $ 13.74万
  • 项目类别:
Elucidating the Prevalence, Etiology, and Trajectories of Symptom Clusters in Early Cancer Survivors
阐明早期癌症幸存者症状群的患病率、病因和轨迹
  • 批准号:
    10116493
  • 财政年份:
    2020
  • 资助金额:
    $ 13.74万
  • 项目类别:
Elucidating the Prevalence, Etiology, and Trajectories of Symptom Clusters in Early Cancer Survivors
阐明早期癌症幸存者症状群的患病率、病因和轨迹
  • 批准号:
    10355546
  • 财政年份:
    2020
  • 资助金额:
    $ 13.74万
  • 项目类别:
Next-generation, pathway-specific, polygenic risk scores
下一代、特定途径、多基因风险评分
  • 批准号:
    10570896
  • 财政年份:
    2020
  • 资助金额:
    $ 13.74万
  • 项目类别:
PharmGKB: pharmacogenomics discovery and implementation
PharmGKB:药物基因组学的发现和实施
  • 批准号:
    10330009
  • 财政年份:
    2020
  • 资助金额:
    $ 13.74万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了